Congress Wealth Management LLC DE Invests $338,000 in Tempus AI, Inc. (NASDAQ:TEM)

Congress Wealth Management LLC DE bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $338,000.

Several other large investors have also recently bought and sold shares of the stock. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $34,000. First Horizon Advisors Inc. increased its holdings in Tempus AI by 207.9% in the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after buying an additional 1,108 shares during the period. FNY Investment Advisers LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at $67,000. IFP Advisors Inc bought a new position in shares of Tempus AI during the 4th quarter worth about $76,000. Finally, US Bancorp DE acquired a new stake in shares of Tempus AI during the 4th quarter valued at about $80,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Performance

TEM opened at $47.83 on Friday. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The firm has a 50-day moving average price of $58.38 and a two-hundred day moving average price of $51.52.

Insider Activity at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 3,240,234 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.75, for a total value of $190,363,747.50. Following the transaction, the chief executive officer now owns 4,895,589 shares of the company’s stock, valued at approximately $287,615,853.75. This trade represents a 39.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew Polovin sold 13,135 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total transaction of $603,947.30. Following the sale, the executive vice president now directly owns 154,171 shares of the company’s stock, valued at approximately $7,088,782.58. This trade represents a 7.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,598,969 shares of company stock valued at $317,194,162 over the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on TEM shares. Morgan Stanley increased their price target on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Loop Capital lowered their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Piper Sandler cut their price objective on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Tempus AI presently has an average rating of “Moderate Buy” and an average price target of $61.18.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.